A Randomized, Double-blind, Placebo-controlled, Phase 1 Study Evaluating the Safety and Pharmacokinetics of Subcutaneous Administration of Single Ascending Doses of DR-01 in Healthy Volunteers
Latest Information Update: 10 Feb 2025
Price :
$35 *
At a glance
- Drugs DR 01 (Primary)
- Indications Alopecia areata; Autoimmune disorders; Large granular lymphocytic leukaemia; Lymphoma; Vitiligo
- Focus Adverse reactions
- Sponsors Dren Bio
- 06 Feb 2025 Planned initiation date changed from 1 Jan 2025 to 1 Feb 2025.
- 03 Feb 2025 Status changed from not yet recruiting to recruiting.
- 16 Jan 2025 New trial record